尿路上皮癌分子分型:全局mRNA分类与肿瘤细胞表型分类的比较
该研究对307例晚期膀胱癌(膀胱切除标本)同时进行全基因组mRNA表达分析和28种蛋白的免疫组化,描述了五种肿瘤细胞表型:尿路上皮样、基因组不稳定型、基底/鳞状细胞癌样、间质样和小细胞/神经内分泌样。研究发现全局mRNA分型与肿瘤细胞表型分型存在系统性不一致,提示需结合分子病理(肿瘤细胞表型)与全局mRNA谱(背景)进行分型。
要点
- 晚期尿路上皮癌可分为五种肿瘤细胞表型,各有分子病理定义。
- 全局mRNA分型与肿瘤细胞表型分型存在系统性不一致。
- 建议联合分子病理与全局mRNA谱进行肌层浸润性膀胱癌分型。
核心结论
- 全局mRNA分型与肿瘤细胞表型分型在肌层浸润性膀胱癌中存在系统性不一致,需结合两者进行分型。
研究设计与样本
- 对307例晚期膀胱癌(膀胱切除标本)进行全基因组基因表达分析和28种蛋白的免疫组化。
主要发现
- 描述了五种晚期尿路上皮癌肿瘤细胞表型:尿路上皮样、基因组不稳定型、基底/鳞状细胞癌样、间质样和小细胞/神经内分泌样。
- 表达尿路上皮分化因子的肿瘤显示终末分化标志物蛋白表达不一致和异常,提示假性分化。
- 不同肿瘤细胞表型的癌症在全局mRNA分析中可能共聚类(汇聚),相同表型的病例可能分开聚类(发散)。
临床怎么用
- 肌层浸润性膀胱癌的亚型分类应结合分子病理(肿瘤细胞表型)和全局mRNA谱(背景)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Global mRNA expression analysis is efficient for phenotypic profiling of tumours, and has been used to define molecular subtypes for almost every major tumour type. A key limitation is that most tumours are communities of both tumour and non-tumour cells. This problem is particularly pertinent for analysis of advanced invasive tumours, which are known to induce major changes and responses in both the tumour and the surrounding tissue. To identify bladder cancer tumour-cell phenotypes and compare classification by tumour-cell phenotype with classification by global gene expression analysis, we analysed 307 advanced bladder cancers (cystectomized) both by genome gene expression analysis and by immunohistochemistry with antibodies for 28 proteins. According to systematic analysis of gene and protein expression data, focusing on key molecular processes, we describe five tumour-cell phenotypes of advanced urothelial carcinoma: urothelial-like, genomically unstable, basal/SCC-like, mesenchymal-like, and small-cell/neuroendocrine-like. We provide molecular pathological definitions for each subtype. Tumours expressing urothelial differentiation factors show inconsistent and abnormal protein expression of terminal differentiation markers, suggesting pseudo-differentiation. Cancers with different tumour-cell phenotypes may co-cluster (converge), and cases with identical tumour-cell phenotypes may cluster apart (diverge), in global mRNA analyses. This divergence/convergence suggests that broad global commonalities related to the invasive process may exist between muscle-invasive tumours regardless of specific tumour-cell phenotype. Hence, there is a systematic disagreement in subtype classification determined by global mRNA profiling and by immunohistochemical profiling at the tumour-cell level. We suggest that a combination of molecular pathology (tumour-cell phenotype) and global mRNA profiling (context) is required for adequate subtype classification of muscle-invasive bladder cancer. © 2017 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.
引用
- Sjödahl G, Eriksson P, Liedberg F, et al. Molecular classification of urothelial carcinoma: global mRNA classification versus tumour-cell phenotype classification. J Pathol. 2017. PMID: 28195647. doi:10.1002/path.4886
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。